Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.

Journal of immunotherapy (Hagerstown, Md. : 1997) - 1 Jan 2000

Antony Paul Andrew, Restifo Nicholas P

Abstract excerpt

CD4+CD25+ T regulatory (Treg) cells control immunologic tolerance to self-antigens and play a role in suppressing antitumor immune responses, but the mechanism of suppression in vivo remains uncertain. Recently, signaling through the high-affinity interleukin-2 (IL-2) receptor has been shown to be critical for Treg cell differentiation and survival in vivo. Mice deficient in IL-2 or its receptor (CD25 or CD122)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adoptive Transfer
Share to Bone Marrow Cells
Share to CD4-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Dendritic Cells

Share to Immunotherapy

Share to Interleukin-2

Share to Lymphoproliferative Disorders

Share to Receptors, Interleukin-2

Source

Open in PubMed Open full text

Identifiers

PMID: 15725955
DOI: 10.1097/01.cji.0000155049.26787.45
PMCID: PMC1242172

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.PMID 15725955Read ↗

Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2.Semantic proximity Read ↗

Differentiating PD-1+ stem-like CD8 T cells towards distinct effectors with enhanced therapeutic potential by an engineered IL-2 cis-targeted to PD-1Semantic proximity Read ↗

CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.Semantic proximity Read ↗

T regulatory cells control T‐cell proliferation partly by the release of soluble CD25 in patients with B‐cell malignanciesSemantic proximity Read ↗

IL-2-driven CD8+ T cell phenotypes: implications for immunotherapy.Semantic proximity Read ↗

Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategiesSemantic proximity Read ↗

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cellsSemantic proximity Read ↗

Regulatory T cell expansion by a highly CD25-dependent IL-2 mutein arrests ongoing autoimmunitySemantic proximity Read ↗

Function of the IL-2R for thymic and peripheral CD4+CD25+ Foxp3+ T regulatory cells.Semantic proximity Read ↗

Cutting edge: expression of TNFR2 defines a maximally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulatory cells.Semantic proximity Read ↗

The antitumor effect induced by an IL-2 'no-alpha' mutein depends on changes in the CD8+ T lymphocyte/Treg cell balance.Semantic proximity Read ↗

Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.